Trends in Adult and Elderly Vaccination: Focus on Vaccination Practices in Tunisia and Morocco.

Redouane Abouqal, Maher Beji, Mohamed Chakroun, Kamal Marhoum El Filali, Jihane Rammaoui, Hela Zaghden
Author Information
  1. Redouane Abouqal: Laboratory of Biostatistics, Clinical and Epidemiological Research, Faculty of Medicine and Pharmacy, Mohammed V University in Rabat, Rabat, Morocco.
  2. Maher Beji: Department of Internal Medicine, Military Hospital Bizerte, Bizerte, Tunisia.
  3. Mohamed Chakroun: Infectious Diseases Department, University Hospital, Monastir, Tunisia.
  4. Kamal Marhoum El Filali: Infectious Diseases Department, Medical School of Casablanca, Casablanca, Morocco.
  5. Jihane Rammaoui: Pfizer Inc., Casablanca, Morocco.
  6. Hela Zaghden: Pfizer Inc., Tunis, Tunisia.

Abstract

Vaccine preventable diseases (VPDs) are a prevailing concern among the adult population, despite availability of vaccines. Unlike pediatric vaccination programs, adult vaccination programs lack the required reach, initiative, and awareness. Clinical studies and real-world data have proven that vaccines effectively reduce the disease burden of VPDs and increase life expectancy. In Tunisia and Morocco, the national immunization program (NIP) focuses more on pediatric vaccination and have limited vaccination programs for adults. However, some vaccination campaigns targeting adults are organized. For example, influenza vaccination campaigns prioritizing at risk adults which includes healthcare professionals, elderly, and patients with comorbidities. Women of childbearing age who have never been vaccinated or whose information is uncertain are recommended to receive tetanus vaccination. Tunisia NIP recommends rubella vaccine mainly for women of childbearing age, while in Morocco, national vaccination campaigns were organized for girls and women (up to 24 years of age) to eliminate rubella. Further, travelers from both countries are recommended to follow all requirements and recommendations in the travel destination. The objective of this manuscript is to provide an overview of the global disease burden of common VPDs including (but not limited to) meningococcal diseases, pneumococcal diseases, hepatitis, and influenza. The review also provides an overview of clinical data and guidelines/recommendations on adult vaccination practices, with special focus on Tunisia and Morocco. Some European and North American countries have concrete recommendations and strategies for adult vaccination to keep the VPDs in check. In Morocco and Tunisia, although, there are sporadic adult vaccination initiatives, the efforts still need upscaling and endorsements to boost vaccination awareness and uptake. There is a need to strengthen strategies in both countries to understand the disease burden and spread awareness. Additional studies are needed to generate economic evidence to support cost-effectiveness of vaccines. Integration of private and public healthcare systems may further improve vaccination uptake in adults.

Keywords

References

  1. Front Public Health. 2021 Jan 20;8:552028 [PMID: 33553082]
  2. Arch Gynecol Obstet. 2012 Mar;285(3):771-7 [PMID: 22159694]
  3. Lancet Infect Dis. 2015 Nov;15(11):1334-46 [PMID: 26453240]
  4. Vaccine. 2014 Apr 25;32(20):2364-74 [PMID: 24606865]
  5. Vaccine. 2013 Nov 4;31(46):5306-13 [PMID: 23727422]
  6. Vaccine. 2021 Mar 12;39(11):1556-1564 [PMID: 33618947]
  7. East Mediterr Health J. 2016 Aug 18;22(5):343-9 [PMID: 27553401]
  8. Hum Vaccin Immunother. 2019;15(2):459-469 [PMID: 30273506]
  9. Clin Infect Dis. 2021 Oct 5;73(7):e1489-e1497 [PMID: 32716500]
  10. BJOG. 2015 Jan;122(1):107-18 [PMID: 25208608]
  11. BMC Infect Dis. 2018 Dec 5;18(1):628 [PMID: 30518331]
  12. Br J Cancer. 2011 Jun 28;105(1):28-37 [PMID: 21629249]
  13. Lancet Infect Dis. 2012 Aug;12(8):597-607 [PMID: 22569484]
  14. J Natl Cancer Inst. 2010 Mar 3;102(5):325-39 [PMID: 20139221]
  15. Hum Vaccin Immunother. 2015;11(1):150-5 [PMID: 25483533]
  16. Pneumonia (Nathan). 2015 Dec 1;6:26-43 [PMID: 31641576]
  17. Hum Vaccin Immunother. 2012 Jul;8(7):881-7 [PMID: 22485048]
  18. J Immunol Res. 2016;2016:7203587 [PMID: 26904695]
  19. Clin Vaccine Immunol. 2010 Apr;17(4):537-44 [PMID: 20164251]
  20. J Adolesc Health. 2016 Aug;59(2 Suppl):S3-S11 [PMID: 27449148]
  21. Nat Rev Immunol. 2011 Nov 04;11(12):865-72 [PMID: 22051890]
  22. Oman Med J. 2018 Jul;33(4):283-290 [PMID: 30038727]
  23. Trop Med Health. 2021 Dec 20;49(1):98 [PMID: 34930506]
  24. Wkly Epidemiol Rec. 2012 Nov 23;87(47):461-76 [PMID: 23210147]
  25. Intervirology. 2022;65(2):80-86 [PMID: 34518480]
  26. Int J Infect Dis. 2018 Apr;69:68-74 [PMID: 29474989]
  27. Vaccine. 2019 Sep 24;37(41):6102-6111 [PMID: 31447126]
  28. Hum Vaccin Immunother. 2016 Sep;12(9):2365-77 [PMID: 27322436]
  29. J Infect Public Health. 2019 Jul - Aug;12(4):472-478 [PMID: 30446255]
  30. Drugs Aging. 2013 May;30(5):309-19 [PMID: 23494214]
  31. EClinicalMedicine. 2020 Nov 23;29-30:100576 [PMID: 33294820]
  32. Public Health. 2016 Oct;139:198-202 [PMID: 27600791]
  33. Hum Vaccin Immunother. 2021 Feb 1;17(2):332-343 [PMID: 32758069]
  34. Pharmacoeconomics. 2017 Jan;35(1):65-82 [PMID: 27637758]
  35. Lancet Oncol. 2012 Jan;13(1):89-99 [PMID: 22075171]
  36. Vaccine. 2018 Feb 8;36(7):921-931 [PMID: 29336923]
  37. Clin Vaccine Immunol. 2015 Feb;22(2):185-92 [PMID: 25499011]
  38. PLoS One. 2016 Feb 25;11(2):e0149540 [PMID: 26914907]
  39. Immunology. 2004 Oct;113(2):163-74 [PMID: 15379976]
  40. Vaccine. 2020 Jun 9;38(28):4405-4411 [PMID: 32387012]
  41. Vaccine. 2021 Sep 7;39(38):5428-5435 [PMID: 34315611]
  42. Hum Vaccin Immunother. 2018 Jul 3;14(7):1773-1778 [PMID: 29553862]
  43. N Engl J Med. 2015 Mar 19;372(12):1114-25 [PMID: 25785969]
  44. MMWR Morb Mortal Wkly Rep. 2014 Sep 19;63(37):822-5 [PMID: 25233284]
  45. Hum Vaccin Immunother. 2020 Jul 2;16(7):1508-1510 [PMID: 31743073]
  46. Hum Vaccin Immunother. 2022 Dec 31;18(1):1-14 [PMID: 34726574]
  47. J Pediatr Adolesc Gynecol. 2016 Jun;29(3):292-8 [PMID: 26612116]
  48. Lancet. 2018 Mar 31;391(10127):1285-1300 [PMID: 29248255]
  49. J Infect Dis. 2021 Sep 30;224(12 Suppl 2):S343-S351 [PMID: 34590138]
  50. Immun Ageing. 2019 Sep 13;16:25 [PMID: 31528180]
  51. Vaccine. 2019 Feb 4;37(6):889-897 [PMID: 30638797]
  52. J Travel Med. 2015 Mar-Apr;22(2):105-14 [PMID: 25483566]
  53. Hum Vaccin Immunother. 2015;11(9):2158-66 [PMID: 26091249]
  54. Hum Vaccin Immunother. 2014;10(12):3700-10 [PMID: 25483681]
  55. J Clin Microbiol. 2011 Nov;49(11):3728-32 [PMID: 21900515]
  56. Eur J Clin Microbiol Infect Dis. 2002 Jun;21(6):483-5 [PMID: 12111610]
  57. Hum Vaccin Immunother. 2019;15(2):444-451 [PMID: 30303436]
  58. BMC Infect Dis. 2018 Aug 29;18(1):436 [PMID: 30157781]
  59. Vaccine. 2013 Nov 4;31(46):5300-5 [PMID: 23727002]
  60. Clin Infect Dis. 2018 Jan 18;66(3):339-345 [PMID: 29029053]
  61. JAMA Netw Open. 2021 Oct 1;4(10):e2128652 [PMID: 34636914]
  62. Vaccine. 2016 Feb 10;34(7):942-9 [PMID: 26752065]
  63. Vaccine. 2020 Jul 14;38(33):5194-5201 [PMID: 32565344]
  64. Int J Infect Dis. 2021 Mar;104:189-197 [PMID: 33227521]
  65. Vaccine. 2019 Mar 14;37(12):1651-1658 [PMID: 30797638]
  66. Int J Infect Dis. 2014 Nov;28:204-10 [PMID: 25316331]
  67. J Clin Microbiol. 2018 Jun 25;56(7): [PMID: 29743304]
  68. BMC Infect Dis. 2020 Aug 26;20(1):627 [PMID: 32842988]
  69. BMJ. 2010 Jul 20;341:c3493 [PMID: 20647284]
  70. PLoS One. 2016 Jun 14;11(6):e0157432 [PMID: 27299955]
  71. Acta Trop. 2021 Apr;216:105822 [PMID: 33421422]
  72. Clin Geriatr Med. 2018 Feb;34(1):131-143 [PMID: 29129213]
  73. Int J Infect Dis. 2022 Feb;115:101-105 [PMID: 34843957]
  74. Travel Med Infect Dis. 2018 Jul - Aug;24:89-100 [PMID: 29860151]
  75. Hum Vaccin Immunother. 2021 Aug 3;17(8):2678-2690 [PMID: 34019468]
  76. Vet Sci. 2020 Mar 01;7(1): [PMID: 32121594]
  77. Pathog Glob Health. 2014 Jan;108(1):11-20 [PMID: 24548156]
  78. Lancet. 2017 Nov 11;390(10108):2143-2159 [PMID: 28886907]
  79. J Glob Health. 2019 Dec;9(2):020421 [PMID: 31673337]
  80. Hum Vaccin. 2011 Dec;7(12):1336-42 [PMID: 22185811]
  81. Vaccine. 2012 Oct 12;30(46):6515-20 [PMID: 22959990]
  82. Infect Dis Ther. 2021 Mar;10(1):399-409 [PMID: 33439463]
  83. Lancet Oncol. 2020 Dec;21(12):1643-1652 [PMID: 33271093]
  84. Popul Health Metr. 2013 Sep 10;11(1):17 [PMID: 24016339]
  85. Ann Med. 2019 Mar;51(2):128-140 [PMID: 31025882]
  86. Clin Vaccine Immunol. 2012 Jun;19(6):881-5 [PMID: 22518014]
  87. Euro Surveill. 2013 Sep 12;18(37): [PMID: 24079399]
  88. Vaccine. 2021 Oct 15;39(43):6422-6436 [PMID: 34489128]
  89. Hum Vaccin Immunother. 2014;10(12):3435-45 [PMID: 25483701]
  90. Libyan J Med. 2020 Dec;15(1):1809223 [PMID: 32822288]
  91. Jpn J Infect Dis. 2018 Nov 22;71(6):402-407 [PMID: 29962480]
  92. Hum Vaccin Immunother. 2018;14(8):1923-1930 [PMID: 29561248]
  93. Vaccine. 2020 Dec 14;38(52):8264-8272 [PMID: 33229108]
  94. Open Forum Infect Dis. 2014 Jul 03;1(2):ofu044 [PMID: 25734116]
  95. Value Health. 2014 Nov;17(7):A607-8 [PMID: 27202107]
  96. Microb Pathog. 2019 Sep;134:103571 [PMID: 31163252]
  97. Hum Vaccin. 2010 Jul;6(7):578-84 [PMID: 20523113]
  98. Hum Vaccin Immunother. 2015;11(7):1825-7 [PMID: 26076136]
  99. Int J Infect Dis. 2015 Sep;38:36-42 [PMID: 26166699]
  100. J Infect. 2017 Jul;75(1):1-11 [PMID: 28455205]
  101. Cancer Med. 2019 Oct;8(14):6195-6211 [PMID: 31305011]
  102. Hum Vaccin Immunother. 2019;15(3):530-539 [PMID: 30648919]
  103. MMWR Morb Mortal Wkly Rep. 2022 Jan 28;71(4):109-117 [PMID: 35085226]
  104. Int Health. 2011 Dec;3(4):270-81 [PMID: 24038500]
  105. Gynecol Oncol. 2008 Sep;110(3 Suppl 2):S4-7 [PMID: 18760711]
  106. Obstet Gynecol. 2009 Dec;114(6):1179-1188 [PMID: 19935017]
  107. EClinicalMedicine. 2020 May 25;23:100353 [PMID: 32639485]
  108. Hum Vaccin Immunother. 2021 Apr 3;17(4):943-949 [PMID: 33326342]
  109. Vaccine. 2014 Jul 16;32(33):4198-205 [PMID: 24930716]
  110. Vaccine. 2018 Oct 29;36(45):6875-6882 [PMID: 29559167]
  111. Sex Transm Infect. 2013 Aug;89(5):358-65 [PMID: 23486859]
  112. MMWR Morb Mortal Wkly Rep. 2019 Nov 22;68(46):1069-1075 [PMID: 31751323]
  113. J Adolesc Health. 2016 Aug;59(2 Suppl):S12-20 [PMID: 27449145]
  114. J Infect Dis. 2013 Jun 1;207(11):1753-63 [PMID: 23242542]
  115. Vaccine. 2019 May 21;37(23):3113-3122 [PMID: 31029515]
  116. Ann Hepatol. 2019 Sep - Oct;18(5):725-729 [PMID: 31176604]
  117. Arch Inst Pasteur Tunis. 2011;88(1-4):35-41 [PMID: 23461141]
  118. Clin Vaccine Immunol. 2015 Apr;22(4):361-73 [PMID: 25651922]
  119. Lancet Respir Med. 2019 Jan;7(1):69-89 [PMID: 30553848]
  120. Lancet Infect Dis. 2010 Dec;10(12):853-61 [PMID: 21075057]
  121. Clin Vaccine Immunol. 2014 Jan;21(1):56-65 [PMID: 24173029]
  122. PLoS One. 2018 Aug 22;13(8):e0201236 [PMID: 30133478]
  123. Vaccines (Basel). 2020 Jan 20;8(1): [PMID: 31968652]
  124. Hum Vaccin Immunother. 2014;10(7):1850-8 [PMID: 25424792]
  125. World J Hepatol. 2012 Mar 27;4(3):68-73 [PMID: 22489258]
  126. Clin Infect Dis. 2018 Apr 3;66(8):1276-1281 [PMID: 29126310]
  127. MMWR Morb Mortal Wkly Rep. 2019 Aug 16;68(32):698-702 [PMID: 31415491]
  128. Nat Rev Microbiol. 2021 May;19(5):287-302 [PMID: 33542518]
  129. Clin Infect Dis. 2019 May 17;68(11):1831-1838 [PMID: 30239637]
  130. PLoS One. 2019 Jul 24;14(7):e0212853 [PMID: 31339884]
  131. Hum Vaccin Immunother. 2017 Sep 2;13(9):2065-2071 [PMID: 28881165]
  132. J Infect Dis. 2010 Dec 15;202(12):1789-99 [PMID: 21067372]
  133. J Pediatric Infect Dis Soc. 2016 Jun;5(2):180-7 [PMID: 26803328]
  134. Vaccine. 2018 Jan 29;36(5):668-674 [PMID: 29289383]
  135. Clin Vaccine Immunol. 2010 May;17(5):840-7 [PMID: 20219881]
  136. Vaccine. 2020 Jan 10;38(2):212-219 [PMID: 31699507]
  137. PLoS One. 2013 Dec 31;8(12):e83431 [PMID: 24391768]
  138. Hum Vaccin Immunother. 2018 May 4;14(5):1107-1115 [PMID: 29211624]
  139. Gynecol Oncol. 2019 Jul;154(1):110-117 [PMID: 30982556]
  140. Int J Infect Dis. 2010 Oct;14(10):e868-75 [PMID: 20655261]
  141. Occup Med (Lond). 2008 Sep;58(6):419-24 [PMID: 18562546]
  142. Clin Microbiol Infect. 2014 May;20(5):391-5 [PMID: 24766477]
  143. JAMA. 1986 Aug 15;256(7):869-72 [PMID: 3016352]
  144. Vaccine. 2015 Nov 27;33(48):6892-901 [PMID: 26144901]
  145. FEMS Microbiol Rev. 2007 Jan;31(1):27-36 [PMID: 17168995]
  146. Infect Dis Ther. 2019 Mar;8(1):63-74 [PMID: 30539417]
  147. Infect Dis Ther. 2021 Sep;10(3):1097-1113 [PMID: 33881713]
  148. Hum Vaccin Immunother. 2016 Aug 2;12(8):2142-2147 [PMID: 27149114]
  149. Tunis Med. 2018 Oct-Nov;96(10-11):696-705 [PMID: 30746663]
  150. Lancet Infect Dis. 2016 Oct;16(10):1154-1168 [PMID: 27373900]
  151. Med Sante Trop. 2019 Feb 1;29(1):92-96 [PMID: 31031259]
  152. Infect Dis Ther. 2021 Jun;10(2):663-685 [PMID: 33751422]
  153. Clin Microbiol Rev. 2007 Apr;20(2):368-89 [PMID: 17428889]
  154. Hum Vaccin Immunother. 2019;15(1):249-255 [PMID: 30215583]
  155. Expert Rev Vaccines. 2019 Jan;18(1):15-30 [PMID: 30526162]
  156. Emerg Infect Dis. 2011 Sep;17(9):1645-50 [PMID: 21888789]
  157. Vaccine. 2019 Jan 3;37(1):109-112 [PMID: 30459070]
  158. Vaccine. 2012 Mar 28;30(15):2556-63 [PMID: 22326642]
  159. Vaccine. 2013 Mar 15;31(12):1569-75 [PMID: 23352429]
  160. Int J Infect Dis. 2015 Nov;40:95-101 [PMID: 26434380]
  161. Biomed Res Int. 2020 Jun 10;2020:7027169 [PMID: 32626758]
  162. BMC Infect Dis. 2015 Oct 06;15:409 [PMID: 26437712]
  163. Health Aff (Millwood). 2016 Nov 1;35(11):2124-2132 [PMID: 27733424]
  164. Lancet. 2009 Jun 6;373(9679):1949-57 [PMID: 19493565]
  165. J Infect Dis. 2014 Jul 15;210(2):192-9 [PMID: 24495910]
  166. Vaccine. 2016 Mar 14;34(12):1465-71 [PMID: 26845739]
  167. J Infect Dis. 2018 Jun 5;218(1):95-108 [PMID: 29767739]
  168. Vaccine. 2015 Jul 17;33(31):3628-35 [PMID: 26093201]
  169. Vaccine. 2018 Sep 18;36(39):5858-5864 [PMID: 30145100]
  170. Drugs. 2003;63(10):1021-51 [PMID: 12699402]
  171. Vaccine. 2013 Aug 2;31(35):3577-84 [PMID: 23688526]

MeSH Term

Adult
Aged
Child
Female
Humans
Influenza Vaccines
Influenza, Human
Morocco
Tunisia
Vaccination

Chemicals

Influenza Vaccines

Word Cloud

Created with Highcharts 10.0.0vaccinationadultTunisiaMoroccodiseasesVPDsadultsvaccinesprogramsawarenessdiseaseburdencampaignsagecountriespediatricstudiesdatanationalNIPlimitedorganizedinfluenzahealthcarechildbearingrecommendedrubellawomenrecommendationsoverviewpracticesstrategiesneeduptakeVaccinepreventableprevailingconcernamongpopulationdespiteavailabilityUnlikelackrequiredreachinitiativeClinicalreal-worldproveneffectivelyreduceincreaselifeexpectancyimmunizationprogramfocusesHowevertargetingexampleprioritizingriskincludesprofessionalselderlypatientscomorbiditiesWomennevervaccinatedwhoseinformationuncertainreceivetetanusrecommendsvaccinemainlygirls24yearseliminatetravelersfollowrequirementstraveldestinationobjectivemanuscriptprovideglobalcommonincludingmeningococcalpneumococcalhepatitisreviewalsoprovidesclinicalguidelines/recommendationsspecialfocusEuropeanNorthAmericanconcretekeepcheckalthoughsporadicinitiativeseffortsstillupscalingendorsementsbooststrengthenunderstandspreadAdditionalneededgenerateeconomicevidencesupportcost-effectivenessIntegrationprivatepublicsystemsmayimproveTrendsAdultElderlyVaccination:FocusVaccinationPracticesvaccine-preventable

Similar Articles

Cited By